10-Q Filing
Filing Information
| Form Type | 10-Q |
| Accession Number | 0001552781-20-000564 |
| Period End Date | 20200930 |
| Filing Date | 20201113 |
| Fiscal Year | 2020 |
| Fiscal Period | Q3 |
| XBRL Instance | swkh-20200930.xml |
Filing Contents
This filing contains the following financial statements:
Balance Sheet
75 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Preferred stock, par value (in dollars per share) |
PreferredStockParOrStatedValuePerShare
|
$0.00 | USD | Point-in-time |
| Preferred stock, par value (in dollars per share) |
PreferredStockParOrStatedValuePerShare
|
$0.00 | USD | Point-in-time |
| Preferred stock, authorized |
PreferredStockSharesAuthorized
|
5.00M | shares | Point-in-time |
| Preferred stock, authorized |
PreferredStockSharesAuthorized
|
5.00M | shares | Point-in-time |
| Preferred stock, issued |
PreferredStockSharesIssued
|
0.00 | shares | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$9.31M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$11.16M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$4.49M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$20.23M | USD | Point-in-time |
| Preferred stock, issued |
PreferredStockSharesIssued
|
0.00 | shares | Point-in-time |
| Interest and accounts receivable, net |
AccountsReceivableNet
|
$4.61M | USD | Point-in-time |
| Preferred stock, outstanding |
PreferredStockSharesOutstanding
|
0.00 | shares | Point-in-time |
| Interest and accounts receivable, net |
AccountsReceivableNet
|
$2.55M | USD | Point-in-time |
| Preferred stock, outstanding |
PreferredStockSharesOutstanding
|
0.00 | shares | Point-in-time |
| Common stock, par value (in dollars per share) |
CommonStockParOrStatedValuePerShare
|
$0.00 | USD | Point-in-time |
| Marketable investments |
MarketableSecurities
|
$1.14M | USD | Point-in-time |
| Common stock, par value (in dollars per share) |
CommonStockParOrStatedValuePerShare
|
$0.00 | USD | Point-in-time |
| Marketable investments |
MarketableSecurities
|
$1.80M | USD | Point-in-time |
| Common stock, authorized |
CommonStockSharesAuthorized
|
250.00M | shares | Point-in-time |
| Other current assets |
OtherAssetsCurrent
|
$1.09M | USD | Point-in-time |
| Common stock, authorized |
CommonStockSharesAuthorized
|
250.00M | shares | Point-in-time |
| Other current assets |
OtherAssetsCurrent
|
$1.91M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$16.97M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$16.60M | USD | Point-in-time |
| Common stock, issued |
CommonStockSharesIssued
|
12.92M | shares | Point-in-time |
| Common stock, issued |
CommonStockSharesIssued
|
12.78M | shares | Point-in-time |
| Common stock, outstanding |
CommonStockSharesOutstanding
|
12.78M | shares | Point-in-time |
| Common stock, outstanding |
CommonStockSharesOutstanding
|
12.92M | shares | Point-in-time |
| Finance receivables, net |
NotesAndLoansReceivableNetCurrent
|
$183.24M | USD | Point-in-time |
| Finance receivables, net |
NotesAndLoansReceivableNetCurrent
|
$172.82M | USD | Point-in-time |
| Marketable investments |
AvailableForSaleSecuritiesDebtSecurities
|
$466.00K | USD | Point-in-time |
| Marketable investments |
AvailableForSaleSecuritiesDebtSecurities
|
$254.00K | USD | Point-in-time |
| Deferred tax asset, net |
DeferredIncomeTaxAssetsNet
|
$25.99M | USD | Point-in-time |
| Deferred tax asset, net |
DeferredIncomeTaxAssetsNet
|
$25.78M | USD | Point-in-time |
| Warrant assets |
WarrantAssets
|
$3.56M | USD | Point-in-time |
| Warrant assets |
WarrantAssets
|
$2.41M | USD | Point-in-time |
| Intangible assets, net |
IntangibleAssetsNetExcludingGoodwill
|
$25.11M | USD | Point-in-time |
| Intangible assets, net |
IntangibleAssetsNetExcludingGoodwill
|
$15.98M | USD | Point-in-time |
| Goodwill |
Goodwill
|
$8.40M | USD | Point-in-time |
| Goodwill |
Goodwill
|
$8.40M | USD | Point-in-time |
| Property, plant and equipment, net |
PropertyPlantAndEquipmentNet
|
$1.29M | USD | Point-in-time |
| Property, plant and equipment, net |
PropertyPlantAndEquipmentNet
|
$3.37M | USD | Point-in-time |
| Other non-current assets |
PrepaidExpenseAndOtherAssets
|
$190.00K | USD | Point-in-time |
| Other non-current assets |
PrepaidExpenseAndOtherAssets
|
$336.00K | USD | Point-in-time |
| Total assets |
Assets
|
$254.37M | USD | Point-in-time |
| Total assets |
Assets
|
$256.80M | USD | Point-in-time |
| Accounts payable and accrued liabilities |
AccountsPayableAndAccruedLiabilitiesCurrent
|
$3.62M | USD | Point-in-time |
| Accounts payable and accrued liabilities |
AccountsPayableAndAccruedLiabilitiesCurrent
|
$3.06M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$3.06M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$3.62M | USD | Point-in-time |
| Contingent consideration payable |
ContingentConsiderationPayable
|
$14.50M | USD | Point-in-time |
| Contingent consideration payable |
ContingentConsiderationPayable
|
$16.46M | USD | Point-in-time |
| Warrant liability |
WarrantsAndRightsOutstanding
|
$76.00K | USD | Point-in-time |
| Other non-current liabilities |
OtherLiabilitiesNoncurrent
|
$1.01M | USD | Point-in-time |
| Other non-current liabilities |
OtherLiabilitiesNoncurrent
|
$203.00K | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$17.84M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$21.10M | USD | Point-in-time |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively |
PreferredStockValue
|
- | USD | Point-in-time |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively |
PreferredStockValue
|
- | USD | Point-in-time |
| Common stock, $0.001 par value; 250,000,000 shares authorized; 12,782,151 and 12,917,348 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively |
CommonStockValue
|
$13.00K | USD | Point-in-time |
| Common stock, $0.001 par value; 250,000,000 shares authorized; 12,782,151 and 12,917,348 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively |
CommonStockValue
|
$13.00K | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$4.43B | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$4.43B | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-4.20B | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-4.20B | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$213.06M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$236.53M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$235.70M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$232.00M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$218.97M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$223.34M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$227.63M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$232.08M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$254.37M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$256.80M | USD | Point-in-time |
Income Statement
88 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Finance receivable interest income, including fees |
InterestAndFeeIncomeLoansAndLeases
|
$21.24M | USD | 3 Qtrs |
| Finance receivable interest income, including fees |
InterestAndFeeIncomeLoansAndLeases
|
$22.74M | USD | 3 Qtrs |
| Finance receivable interest income, including fees |
InterestAndFeeIncomeLoansAndLeases
|
$6.20M | USD | 1 Quarter |
| Finance receivable interest income, including fees |
InterestAndFeeIncomeLoansAndLeases
|
$7.87M | USD | 1 Quarter |
| Pharmaceutical development |
PharmaceuticalDevelopmentRevenue
|
$149.00K | USD | 3 Qtrs |
| Pharmaceutical development |
PharmaceuticalDevelopmentRevenue
|
$2.78M | USD | 1 Quarter |
| Pharmaceutical development |
PharmaceuticalDevelopmentRevenue
|
$3.08M | USD | 3 Qtrs |
| Pharmaceutical development |
PharmaceuticalDevelopmentRevenue
|
$149.00K | USD | 1 Quarter |
| Other |
RevenueNotFromContractWithCustomerOther
|
- | USD | 1 Quarter |
| Other |
RevenueNotFromContractWithCustomerOther
|
$2.00K | USD | 1 Quarter |
| Other |
RevenueNotFromContractWithCustomerOther
|
$4.00K | USD | 3 Qtrs |
| Other |
RevenueNotFromContractWithCustomerOther
|
$9.00K | USD | 3 Qtrs |
| Total revenues |
Revenues
|
$10.65M | USD | 1 Quarter |
| Total revenues |
Revenues
|
$25.82M | USD | 3 Qtrs |
| Total revenues |
Revenues
|
$6.35M | USD | 1 Quarter |
| Total revenues |
Revenues
|
$21.40M | USD | 3 Qtrs |
| Provision for credit losses |
ProvisionForLoanAndLeaseLosses
|
- | USD | 1 Quarter |
| Provision for credit losses |
ProvisionForLoanAndLeaseLosses
|
- | USD | 1 Quarter |
| Provision for credit losses |
ProvisionForLoanAndLeaseLosses
|
- | USD | 3 Qtrs |
| Provision for credit losses |
ProvisionForLoanAndLeaseLosses
|
$609.00K | USD | 3 Qtrs |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
- | USD | 1 Quarter |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
- | USD | 1 Quarter |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
$163.00K | USD | 3 Qtrs |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
- | USD | 3 Qtrs |
| Interest expense |
InterestExpense
|
$259.00K | USD | 3 Qtrs |
| Interest expense |
InterestExpense
|
$79.00K | USD | 1 Quarter |
| Interest expense |
InterestExpense
|
$365.00K | USD | 3 Qtrs |
| Interest expense |
InterestExpense
|
$101.00K | USD | 1 Quarter |
| Pharmaceutical manufacturing, research and development expense |
ResearchAndDevelopmentExpense
|
$286.00K | USD | 3 Qtrs |
| Pharmaceutical manufacturing, research and development expense |
ResearchAndDevelopmentExpense
|
$3.31M | USD | 3 Qtrs |
| Pharmaceutical manufacturing, research and development expense |
ResearchAndDevelopmentExpense
|
$1.18M | USD | 1 Quarter |
| Pharmaceutical manufacturing, research and development expense |
ResearchAndDevelopmentExpense
|
$286.00K | USD | 1 Quarter |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$1.96M | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
- | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$174.00K | USD | 1 Quarter |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
- | USD | 1 Quarter |
| Depreciation and amortization expense |
DepreciationAndAmortization
|
$358.00K | USD | 1 Quarter |
| Depreciation and amortization expense |
DepreciationAndAmortization
|
$9.63M | USD | 3 Qtrs |
| Depreciation and amortization expense |
DepreciationAndAmortization
|
$368.00K | USD | 3 Qtrs |
| Depreciation and amortization expense |
DepreciationAndAmortization
|
$2.68M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$5.30M | USD | 3 Qtrs |
| General and administrative |
GeneralAndAdministrativeExpense
|
$2.53M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$2.72M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$8.21M | USD | 3 Qtrs |
| Total costs and expenses |
CostsAndExpenses
|
$6.67M | USD | 1 Quarter |
| Total costs and expenses |
CostsAndExpenses
|
$3.44M | USD | 1 Quarter |
| Total costs and expenses |
CostsAndExpenses
|
$6.82M | USD | 3 Qtrs |
| Total costs and expenses |
CostsAndExpenses
|
$23.65M | USD | 3 Qtrs |
| Unrealized net gain (loss) on warrants |
UnrealizedNetLossGainOnWarrants
|
$-1.15M | USD | 3 Qtrs |
| Unrealized net gain (loss) on warrants |
UnrealizedNetLossGainOnWarrants
|
$-1.15M | USD | 1 Quarter |
| Unrealized net gain (loss) on warrants |
UnrealizedNetLossGainOnWarrants
|
$87.00K | USD | 1 Quarter |
| Unrealized net gain (loss) on warrants |
UnrealizedNetLossGainOnWarrants
|
$-146.00K | USD | 3 Qtrs |
| Unrealized net (loss) gain on equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$-178.00K | USD | 1 Quarter |
| Unrealized net (loss) gain on equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$1.79M | USD | 3 Qtrs |
| Unrealized net (loss) gain on equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$1.79M | USD | 1 Quarter |
| Unrealized net (loss) gain on equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$-666.00K | USD | 3 Qtrs |
| Income before provision (benefit) for income taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$359.00K | USD | 3 Qtrs |
| Income before provision (benefit) for income taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$3.54M | USD | 1 Quarter |
| Income before provision (benefit) for income taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$16.21M | USD | 3 Qtrs |
| Income before provision (benefit) for income taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$3.89M | USD | 1 Quarter |
| Provision (benefit) for income taxes |
IncomeTaxExpenseBenefit
|
$-451.00K | USD | 1 Quarter |
| Provision (benefit) for income taxes |
IncomeTaxExpenseBenefit
|
$1.17M | USD | 3 Qtrs |
| Provision (benefit) for income taxes |
IncomeTaxExpenseBenefit
|
$-199.00K | USD | 3 Qtrs |
| Provision (benefit) for income taxes |
IncomeTaxExpenseBenefit
|
$-614.00K | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$15.04M | USD | 3 Qtrs |
| Consolidated net income |
ProfitLoss
|
$4.16M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$876.00K | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$4.33M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$-4.66M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$558.00K | USD | 3 Qtrs |
| Consolidated net income |
ProfitLoss
|
$6.56M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$4.34M | USD | 1 Quarter |
| Basic (in dollars per share) |
EarningsPerShareBasic
|
$0.04 | USD | 3 Qtrs |
| Basic (in dollars per share) |
EarningsPerShareBasic
|
$1.17 | USD | 3 Qtrs |
| Basic (in dollars per share) |
EarningsPerShareBasic
|
$0.32 | USD | 1 Quarter |
| Basic (in dollars per share) |
EarningsPerShareBasic
|
$0.34 | USD | 1 Quarter |
| Diluted (in dollars per share) |
EarningsPerShareDiluted
|
$0.34 | USD | 1 Quarter |
| Diluted (in dollars per share) |
EarningsPerShareDiluted
|
$0.04 | USD | 3 Qtrs |
| Diluted (in dollars per share) |
EarningsPerShareDiluted
|
$1.17 | USD | 3 Qtrs |
| Diluted (in dollars per share) |
EarningsPerShareDiluted
|
$0.32 | USD | 1 Quarter |
| Basic (in shares) |
WeightedAverageNumberOfSharesOutstandingBasic
|
12.90M | shares | 1 Quarter |
| Basic (in shares) |
WeightedAverageNumberOfSharesOutstandingBasic
|
12.90M | shares | 1 Quarter |
| Basic (in shares) |
WeightedAverageNumberOfSharesOutstandingBasic
|
12.89M | shares | 3 Qtrs |
| Basic (in shares) |
WeightedAverageNumberOfSharesOutstandingBasic
|
12.90M | shares | 3 Qtrs |
| Diluted (in shares) |
WeightedAverageNumberOfDilutedSharesOutstanding
|
12.91M | shares | 1 Quarter |
| Diluted (in shares) |
WeightedAverageNumberOfDilutedSharesOutstanding
|
12.92M | shares | 1 Quarter |
| Diluted (in shares) |
WeightedAverageNumberOfDilutedSharesOutstanding
|
12.91M | shares | 3 Qtrs |
| Diluted (in shares) |
WeightedAverageNumberOfDilutedSharesOutstanding
|
12.90M | shares | 3 Qtrs |
Cash Flow Statement
82 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Consolidated net (loss) income |
ProfitLoss
|
$15.04M | USD | 3 Qtrs |
| Consolidated net (loss) income |
ProfitLoss
|
$4.16M | USD | 1 Quarter |
| Consolidated net (loss) income |
ProfitLoss
|
$876.00K | USD | 1 Quarter |
| Consolidated net (loss) income |
ProfitLoss
|
$4.33M | USD | 1 Quarter |
| Consolidated net (loss) income |
ProfitLoss
|
$-4.66M | USD | 1 Quarter |
| Consolidated net (loss) income |
ProfitLoss
|
$558.00K | USD | 3 Qtrs |
| Consolidated net (loss) income |
ProfitLoss
|
$6.56M | USD | 1 Quarter |
| Consolidated net (loss) income |
ProfitLoss
|
$4.34M | USD | 1 Quarter |
| Provision for loan credit losses |
ProvisionForLoanAndLeaseLosses
|
- | USD | 1 Quarter |
| Provision for loan credit losses |
ProvisionForLoanAndLeaseLosses
|
- | USD | 1 Quarter |
| Provision for loan credit losses |
ProvisionForLoanAndLeaseLosses
|
- | USD | 3 Qtrs |
| Provision for loan credit losses |
ProvisionForLoanAndLeaseLosses
|
$609.00K | USD | 3 Qtrs |
| Impairment expense |
AssetImpairmentCharges
|
- | USD | 3 Qtrs |
| Impairment expense |
AssetImpairmentCharges
|
$163.00K | USD | 3 Qtrs |
| Amortization of debt issuance costs |
AmortizationOfFinancingCosts
|
$141.00K | USD | 3 Qtrs |
| Amortization of debt issuance costs |
AmortizationOfFinancingCosts
|
$140.00K | USD | 3 Qtrs |
| Deferred income taxes |
DeferredIncomeTaxesAndTaxCredits
|
$1.17M | USD | 3 Qtrs |
| Deferred income taxes |
DeferredIncomeTaxesAndTaxCredits
|
$-206.00K | USD | 3 Qtrs |
| Change in fair value of warrants |
FairValueAdjustmentOfWarrants
|
$146.00K | USD | 3 Qtrs |
| Change in fair value of warrants |
FairValueAdjustmentOfWarrants
|
$1.15M | USD | 3 Qtrs |
| Change in fair value of equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$-178.00K | USD | 1 Quarter |
| Change in fair value of equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$1.79M | USD | 3 Qtrs |
| Change in fair value of equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$1.79M | USD | 1 Quarter |
| Change in fair value of equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$-666.00K | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$1.96M | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
- | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$174.00K | USD | 1 Quarter |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
- | USD | 1 Quarter |
| Loan discount amortization and fee accretion |
AmortizationOfDeferredLoanOriginationFeesNet
|
$-122.00K | USD | 3 Qtrs |
| Loan discount amortization and fee accretion |
AmortizationOfDeferredLoanOriginationFeesNet
|
$1.60M | USD | 3 Qtrs |
| Interest paid-in-kind |
PaidInKindInterest
|
$875.00K | USD | 3 Qtrs |
| Interest paid-in-kind |
PaidInKindInterest
|
$2.37M | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$88.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$337.00K | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$179.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$147.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$102.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$187.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$549.00K | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$183.00K | USD | 1 Quarter |
| Interest income in excess of cash collected |
InterestIncomeInExcessOfCashCollected
|
- | USD | 3 Qtrs |
| Interest income in excess of cash collected |
InterestIncomeInExcessOfCashCollected
|
$-82.00K | USD | 3 Qtrs |
| Depreciation and amortization expense |
DepreciationAmortizationAndAccretionNet
|
$368.00K | USD | 3 Qtrs |
| Depreciation and amortization expense |
DepreciationAmortizationAndAccretionNet
|
$9.63M | USD | 3 Qtrs |
| Interest and accounts receivable |
IncreaseDecreaseInAccountsReceivable
|
$-2.05M | USD | 3 Qtrs |
| Interest and accounts receivable |
IncreaseDecreaseInAccountsReceivable
|
$-112.00K | USD | 3 Qtrs |
| Other assets |
IncreaseDecreaseInOtherCurrentAssets
|
$-252.00K | USD | 3 Qtrs |
| Other assets |
IncreaseDecreaseInOtherCurrentAssets
|
$-819.00K | USD | 3 Qtrs |
| Accounts payable and other liabilities |
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
$-1.43M | USD | 3 Qtrs |
| Accounts payable and other liabilities |
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
$1.43M | USD | 3 Qtrs |
| Net cash provided by operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$9.21M | USD | 3 Qtrs |
| Net cash provided by operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$13.39M | USD | 3 Qtrs |
| Acquisition of business, net of cash acquired |
PaymentsToAcquireBusinessesNetOfCashAcquired
|
- | USD | 3 Qtrs |
| Acquisition of business, net of cash acquired |
PaymentsToAcquireBusinessesNetOfCashAcquired
|
$19.71M | USD | 3 Qtrs |
| Investment in equity securities |
IncreaseDecreaseInTradingSecurities
|
$159.00K | USD | 3 Qtrs |
| Investment in equity securities |
IncreaseDecreaseInTradingSecurities
|
- | USD | 3 Qtrs |
| Investment in finance receivables |
PaymentsToAcquireFinanceReceivables
|
$41.04M | USD | 3 Qtrs |
| Investment in finance receivables |
PaymentsToAcquireFinanceReceivables
|
$12.46M | USD | 3 Qtrs |
| Repayment of finance receivables |
ProceedsRepaymentOfFinanceReceivables
|
$5.93M | USD | 3 Qtrs |
| Repayment of finance receivables |
ProceedsRepaymentOfFinanceReceivables
|
$32.63M | USD | 3 Qtrs |
| Corporate debt security principal payment |
MarketableInvestmentPrincipalPayment
|
$49.00K | USD | 3 Qtrs |
| Corporate debt security principal payment |
MarketableInvestmentPrincipalPayment
|
$49.00K | USD | 3 Qtrs |
| Purchases of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
- | USD | 3 Qtrs |
| Purchases of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
$2.35M | USD | 3 Qtrs |
| Other |
PaymentsForProceedsFromOtherInvestingActivities
|
$100.00K | USD | 3 Qtrs |
| Other |
PaymentsForProceedsFromOtherInvestingActivities
|
$220.00K | USD | 3 Qtrs |
| Net cash provided by (used in) investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$-9.05M | USD | 3 Qtrs |
| Net cash provided by (used in) investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$-28.33M | USD | 3 Qtrs |
| Repurchases of common stock, including fees and expenses |
PaymentsForRepurchaseOfCommonStock
|
$809.00K | USD | 3 Qtrs |
| Repurchases of common stock, including fees and expenses |
PaymentsForRepurchaseOfCommonStock
|
$2.00M | USD | 3 Qtrs |
| Net cash used in financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$-2.00M | USD | 3 Qtrs |
| Net cash used in financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$-809.00K | USD | 3 Qtrs |
| Net decrease in cash and cash equivalents |
CashAndCashEquivalentsPeriodIncreaseDecrease
|
$-15.74M | USD | 3 Qtrs |
| Net decrease in cash and cash equivalents |
CashAndCashEquivalentsPeriodIncreaseDecrease
|
$-1.84M | USD | 3 Qtrs |
| Cash and cash equivalents at beginning of period |
CashAndCashEquivalentsAtCarryingValue
|
$9.31M | USD | Point-in-time |
| Cash and cash equivalents at beginning of period |
CashAndCashEquivalentsAtCarryingValue
|
$11.16M | USD | Point-in-time |
| Cash and cash equivalents at beginning of period |
CashAndCashEquivalentsAtCarryingValue
|
$4.49M | USD | Point-in-time |
| Cash and cash equivalents at beginning of period |
CashAndCashEquivalentsAtCarryingValue
|
$20.23M | USD | Point-in-time |
| Cash and cash equivalents at end of period |
CashAndCashEquivalentsAtCarryingValue
|
$9.31M | USD | Point-in-time |
| Cash and cash equivalents at end of period |
CashAndCashEquivalentsAtCarryingValue
|
$11.16M | USD | Point-in-time |
| Cash and cash equivalents at end of period |
CashAndCashEquivalentsAtCarryingValue
|
$4.49M | USD | Point-in-time |
| Cash and cash equivalents at end of period |
CashAndCashEquivalentsAtCarryingValue
|
$20.23M | USD | Point-in-time |
Stockholders Equity
45 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Beginning Balance |
StockholdersEquity
|
$213.06M | USD | Point-in-time |
| Beginning Balance |
StockholdersEquity
|
$236.53M | USD | Point-in-time |
| Beginning Balance |
StockholdersEquity
|
$235.70M | USD | Point-in-time |
| Beginning Balance |
StockholdersEquity
|
$232.00M | USD | Point-in-time |
| Beginning Balance |
StockholdersEquity
|
$218.97M | USD | Point-in-time |
| Beginning Balance |
StockholdersEquity
|
$223.34M | USD | Point-in-time |
| Beginning Balance |
StockholdersEquity
|
$227.63M | USD | Point-in-time |
| Beginning Balance |
StockholdersEquity
|
$232.08M | USD | Point-in-time |
| Stock-based compensation |
ShareBasedCompensation
|
$88.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$337.00K | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$179.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$147.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$102.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$187.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$549.00K | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$183.00K | USD | 1 Quarter |
| Issuance of common stock in lieu of payment of employee cash bonuses |
StockIssuedDuringPeriodValueEmployeeBenefitPlan
|
$60.00K | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Repurchases of common stock in open market |
StockRepurchasedDuringPeriodValue
|
$62.00K | USD | 1 Quarter |
| Repurchases of common stock in open market |
StockRepurchasedDuringPeriodValue
|
$11.00K | USD | 1 Quarter |
| Repurchases of common stock in open market |
StockRepurchasedDuringPeriodValue
|
$745.00K | USD | 1 Quarter |
| Repurchases of common stock in open market |
StockRepurchasedDuringPeriodValue
|
$1.03M | USD | 1 Quarter |
| Repurchases of common stock in open market |
StockRepurchasedDuringPeriodValue
|
$53.00K | USD | 1 Quarter |
| Repurchases of common stock in open market |
StockRepurchasedDuringPeriodValue
|
$903.00K | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$15.04M | USD | 3 Qtrs |
| Net income |
ProfitLoss
|
$4.16M | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$876.00K | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$4.33M | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$-4.66M | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$558.00K | USD | 3 Qtrs |
| Net income |
ProfitLoss
|
$6.56M | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$4.34M | USD | 1 Quarter |
| Ending Balance |
StockholdersEquity
|
$213.06M | USD | Point-in-time |
| Ending Balance |
StockholdersEquity
|
$236.53M | USD | Point-in-time |
| Ending Balance |
StockholdersEquity
|
$235.70M | USD | Point-in-time |
| Ending Balance |
StockholdersEquity
|
$232.00M | USD | Point-in-time |
| Ending Balance |
StockholdersEquity
|
$218.97M | USD | Point-in-time |
| Ending Balance |
StockholdersEquity
|
$223.34M | USD | Point-in-time |
| Ending Balance |
StockholdersEquity
|
$227.63M | USD | Point-in-time |
| Ending Balance |
StockholdersEquity
|
$232.08M | USD | Point-in-time |
Comprehensive Income
16 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Consolidated net income |
ProfitLoss
|
$15.04M | USD | 3 Qtrs |
| Consolidated net income |
ProfitLoss
|
$4.16M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$876.00K | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$4.33M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$-4.66M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$558.00K | USD | 3 Qtrs |
| Consolidated net income |
ProfitLoss
|
$6.56M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$4.34M | USD | 1 Quarter |
| Other comprehensive income, net of tax |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
- | USD | 3 Qtrs |
| Other comprehensive income, net of tax |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
- | USD | 1 Quarter |
| Other comprehensive income, net of tax |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
- | USD | 1 Quarter |
| Other comprehensive income, net of tax |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
- | USD | 3 Qtrs |
| Comprehensive income |
ComprehensiveIncomeNetOfTax
|
$4.34M | USD | 1 Quarter |
| Comprehensive income |
ComprehensiveIncomeNetOfTax
|
$15.04M | USD | 3 Qtrs |
| Comprehensive income |
ComprehensiveIncomeNetOfTax
|
$558.00K | USD | 3 Qtrs |
| Comprehensive income |
ComprehensiveIncomeNetOfTax
|
$4.16M | USD | 1 Quarter |
Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.